NCT06881251

A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants With Moderate to Severe AD

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 256 (actual)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate how well JNJ-95475939 works as compared to placebo in participants with moderate to severe atopic dermatitis.

Conditions

• Dermatitis, Atopic

Interventions

Type	Name	Description
DRUG	Dupilumab	Dupilumab will be administered subcutaneously.
DRUG	JNJ-95475939	JNJ-95475939 will be administered subcutaneously.
DRUG	Placebo	Placebo will be administered subcutaneously.

Timeline

• Start date: 2025-02-26
• Primary completion: 2026-03-09
• Completion: 2026-03-26
• First posted: 2025-03-18
• Last updated: 2026-03-13

Locations

71 sites across 9 countries: United States, Argentina, Brazil, Canada, Germany, Japan, Poland, Spain, United Kingdom

Regulatory

• FDA-regulated drug study